1887

Journal of Medical Microbiology logo

Volume 67, Issue 9

Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile Free

Abstract

Purpose. Clostridium difficile infection (CDI) is an increasing cause of nosocomial diarrhoea worldwide, which has been partly attributed to the emergence of hypervirulent strains including C. difficile BI/NAP1/ribotype 027 and BK/NAP7/ribotype 078. Cadazolid is a new antibiotic currently in late-stage clinical studies for the treatment of CDI. The present study evaluated the in vitro bactericidal effect of cadazolid and comparator antibiotics against four C. difficile strains. The data demonstrate the potent and bactericidal activity of cadazolid against different ribotypes of C. difficile.

Methodology. MICs for test antibiotics were determined in brain– heart infusion-supplemented broth (BHIS) containing 5 g l yeast extract and 0.025 % (w/v) l-cysteine. Time-kill kinetics to investigate the rate of killing of each antibiotic at sub- and supra-MIC concentrations were performed at concentrations of 0.5, 1, 2, 4, 8 or 16× the MIC of cadazolid, vancomycin and fidaxomicin at intervals over a 48 h period.

Results/key findings. Cadazolid-mediated killing of C. difficile was faster and occurred at lower concentrations than observed for vancomycin, while potency and killing was largely comparable to those observed for fidaxomicin. Notably, cadazolid also displayed a potent bactericidal effect against fluoroquinolone-resistant hypervirulent ribotype 027 and 078 strains. C. difficile spore formation was largely inhibited by all three antibiotics at concentrations >1× MIC; however, none were able to eliminate spores effectively, which were present at the start of the experiment.

Conclusion. The data presented here demonstrate the potent in vitro bactericidal activity of cadazolid against different ribotypes of C. difficile, although on a limited set of strains.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): cadazolid , CDI , Clostridium difficile and time-kill kinetics
© 2018 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000808
2018-07-27
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/9/1402.html?itemId=/content/journal/jmm/10.1099/jmm.0.000808&mimeType=html&fmt=ahah

References

  1. Garneau JR, Valiquette L, Fortier LC. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014; 14:29 [View Article][PubMed]
     [Google Scholar]
  2. Hookman P, Barkin JS. Clostridium associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15:1554–1580 [View Article]
     [Google Scholar]
  3. O'Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009; 136:1913–1924 [View Article][PubMed]
     [Google Scholar]
  4. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentek A et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother 2011; 58:901–908
     [Google Scholar]
  5. Garey KW, Sethi S, Yadav Y, Dupont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70:298–304 [View Article][PubMed]
     [Google Scholar]
  6. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281–289 [View Article][PubMed]
     [Google Scholar]
  7. Caspers P, Locher HH, Pfaff P, Diggelmann S, Rueedi G et al. Different resistance mechanisms for cadazolid and linezolid in Clostridium difficile found by whole-genome sequencing analysis. Antimicrob Agents Chemother 2017; 61:e00384-17 [View Article][PubMed]
     [Google Scholar]
  8. Locher HH, Caspers P, Bruyère T, Schroeder S, Pfaff P et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 2014; 58:901–908 [View Article][PubMed]
     [Google Scholar]
  9. Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 2014; 58:892–900 [View Article][PubMed]
     [Google Scholar]
  10. Rashid MU, Lozano HM, Weintraub A, Nord CE. In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden. Anaerobe 2013; 20:32–35 [View Article][PubMed]
     [Google Scholar]
  11. Chilton CH, Crowther GS, Baines SD, Todhunter SL, Freeman J et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother 2014; 69:697–705 [View Article][PubMed]
     [Google Scholar]
  12. Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN et al. Multicenter, double-blind, randomized, Phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2015; 59:6266–6273 [View Article][PubMed]
     [Google Scholar]
  13. CLSI Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard -, 7th ed, M11-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2007
     [Google Scholar]
  14. CLSI Performance Standards for Antimicrobial Susceptibility Testing: Approved Standard -, 28th ed, M100-S28. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
     [Google Scholar]
  15. Corbett D, Wise A, Birchall S, Warn P, Baines SD et al. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother 2015; 70:1751–1756 [View Article][PubMed]
     [Google Scholar]
  16. Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011; 60:1213–1217 [View Article][PubMed]
     [Google Scholar]
  17. Burns DA, Heeg D, Cartman ST, Minton NP. Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027. PLoS One 2011; 6:e24894 [View Article][PubMed]
     [Google Scholar]
  18. Goldstein EJ, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012; 55:S143–S148 [View Article][PubMed]
     [Google Scholar]
  19. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55:S162–S169 [View Article][PubMed]
     [Google Scholar]
  20. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998; 36:2240–2247[PubMed]
     [Google Scholar]
  21. Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004; 42:5710–5714 [View Article][PubMed]
     [Google Scholar]
  22. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66:2018–2025[PubMed]
     [Google Scholar]
  23. Fawley WN, Wilcox MH. Clostridium difficile Ribotyping Network for England and Northern Ireland An enhanced DNA fingerprinting service to investigate potential Clostridium difficile infection case clusters sharing the same PCR ribotype. J Clin Microbiol 2011; 49:4333–4337 [View Article][PubMed]
     [Google Scholar]
  24. Stabler RA, He M, Dawson L, Martin M, Valiente E et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 2009; 10:R102–115 [View Article][PubMed]
     [Google Scholar]
  25. Rolfe RD, Finegold SM. Purification and characterization of Clostridium difficile toxin. Infect Immun 1979; 25:191–201[PubMed]
     [Google Scholar]
  26. Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B et al. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 2000; 186:307–312 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000808
Loading
Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile
J. Med. Microbiol. 67, 1402 (2018); https://doi.org/10.1099/jmm.0.000808
/content/journal/jmm/10.1099/jmm.0.000808
/content/journal/jmm/10.1099/jmm.0.000808
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error